
Last updated: 2026-09-07 18:39:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Lantern Pharma Inc. (LTRN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.91, with a market capitalization of $24.35M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.11 to $4.70. This page covers its latest market performance, valuation, price trends and company information.
$24.35M | |
$1.86 | |
$24.84 | |
$1.11 | |
$1.87 | |
127.83K | |
145.07K | |
-- | |
$4.70 | |
$1.11 | |
-- | |
-- |
Lantern Pharma Inc. (LTRN) last closed at $1.87 as of 2026-09-04 23:31:00, unchanged from the previous close of $1.87.
During the latest regular trading session, LTRN traded between $1.11 and $24.84, with a volume of 127.83K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Lantern Pharma Inc. (LTRN) moved from $2.16 to $1.91, representing a decline of 11.81% ($0.26).
The stock traded between $1.81 and $2.30 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 155.02 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 22.1%
LTRN is currently trading at $1.91, placing it 22.1% of the way from its 52-week low of $1.11 to its 52-week high of $4.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 16 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lantern Pharma Inc. (LTRN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.